Genetic Screening Testing for Preventive Health Market Forecast with Size and Share Analysis 2025 to 2034
Share With :
Global Genetic Screening Testing for Preventive Health Market is predicted to grow at a 11.8% CAGR during the forecast period for 2025 to 2034.
Genetic Screening Testing for Preventive Health Market Size, Share & Trends Analysis Report By test type (Carrier Screening Tests (Expanded Carrier Screening, Targeted Carrier Screening), Non-Invasive Prenatal Tests, Preimplantation Genetic Testing, And Newborn Screening), Technology (NGS, Microarray, PCR, FISH), Application (Oncology, Cardiovascular Diseases, Reproductive Health, Neurodegenerative Health, Rare Diseases), And End-User (Hospitals And Diagnostic Laboratories, Dtc Companies, Genetic Counselling Services), By Region, And By Segment Forecasts, 2025 to 2034.
Analyzing a person's genetic composition to forecast their risk of contracting specific diseases or ailments in the future is known as genetic screening tests for preventative health. These tests are intended to detect genetic susceptibilities to several illnesses, including diabetes, cancer, heart disease, and other inherited conditions. Due to factors such as growing consumer interest in personalized treatment, the development of preventive healthcare policies, and technical improvements, the market for genetic screening tests in preventive health has been expanding quickly. From detecting particular gene mutations to determining a person's risk for chronic illnesses, genetic testing for preventative health may do it all. Through early lifestyle modifications or medical interventions, these tests assist people in taking proactive measures to manage their health and possibly lower their chance of acquiring illnesses. The market for genetic screening testing for preventive health encompasses carrier screening for inherited diseases and genetic testing for common and uncommon genetic abnormalities.
In addition, more people are realizing the advantages of early disease detection and management, which highlights the significance of preventative healthcare. Organizations, medical experts, and public health campaigns have emphasized the importance of genetic screening in identifying health problems before symptoms manifest, which has increased market demand.
• Exact Science
• Labcorp Genetics Inc.
• Dante Labs US
• Myriad Genetics, Inc.
• Blueprint Genetics
• Ambry Genetics
• Revvity
• Laboratory Corporation of America Holdings
• BGI Group
• Genex Diagnostics Inc.
• Sonic Healthcare
• Fulgent Genetics
The genetic screening testing for preventive health market is segmented based on test type, technology, application, and end-user. Based on test type, the market is segmented into carrier screening tests (expanded carrier screening, targeted carrier screening), non-invasive prenatal tests, preimplantation genetic testing, and newborn screening. By technology, the market is segmented into NGS, Microarray, PCR, FISH, and others. The market is segmented by application into oncology, cardiovascular diseases, reproductive health, neurodegenerative health, rare diseases, and others. The market is segmented by end-users into hospitals and diagnostic laboratories, dtc companies, genetic counselling services, and other end-users.
Based On The Test Type, The Non-Invasive Prenatal Test Segment Is Accounted As A Major Contributor To The Genetic Screening Testing For Preventive Health Market
The Non-Invasive Prenatal Test category is expected to hold a major global market share in 2024 driven by improvements in genetic testing methods, growing mother age, and growing awareness of early fetal health screening. Pregnant women and medical professionals are more likely to use NIPT since it provides a safer and more accurate substitute for more intrusive treatments like amniocentesis. Further driving market expansion is the growing accessibility of NIPT in hospitals, diagnostic facilities, and direct-to-consumer platforms. Furthermore, NIPT is becoming a more popular option for prenatal screening due to its accessibility, rising insurance coverage, decreasing test costs, and regulatory approvals.
The Polymerase Chain Reaction (PCR) category's high sensitivity, specificity, and quick turnaround time for identifying genetic alterations and disease predispositions are driving its rise in the Genetic Screening Testing for Preventive Health Market. PCR is an essential technique for risk assessment, early illness identification, and individualized preventive healthcare measures because of its capacity to amplify minute DNA samples. The need for PCR-based genetic screening is being driven by the rising incidence of genetic illnesses as well as increased knowledge of preventative health measures. The accuracy and efficiency of PCR technology are being further improved by developments like digital PCR and real-time quantitative PCR (qPCR), which will increase their use in clinical and research contexts.
The North American Genetic Screening Testing for Preventive Health market is expected to register the highest market share in revenue in the near future driven by advancements in technology, a robust healthcare system, and growing consumer awareness. The United States, in particular, is a prominent player because of its established healthcare system, extensive research on genetic testing, and increasing focus on tailored therapy. Additionally, the advent of direct-to-consumer genetic testing businesses like 23andMe has increased market penetration. In addition, Asia Pacific is projected to grow rapidly in the global Genetic Screening Testing for Preventive Health market fueled by growing healthcare infrastructure investment, economic growth, and healthcare awareness. China, Japan, India, and South Korea are among the nations that are becoming crucial genetic testing markets. Japan and South Korea are developing the standard for cutting-edge medical technology despite China and India having sizable populations with a wide range of genetic profiles.
| Report Attribute | Specifications |
| Growth Rate CAGR | CAGR of 11.8% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Bn and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Product, Application |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; Japan; South Korea; Southeast Asia |
| Competitive Landscape | Exact Science, Labcorp Genetics Inc., Dante Labs US, Myriad Genetics, Inc., Blueprint Genetics, Ambry Genetics, Revvity, Laboratory Corporation of America Holdings, BGI Group, Genex Diagnostics Inc., Sonic Healthcare, and Fulgent Genetics. |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Genetic Screening Testing for Preventive Health Market By Test Type-
• Carrier Screening Test
• Non-Invasive Prenatal Test
• Preimplantation Genetic Testing
• Newborn Screening
Genetic Screening Testing for Preventive Health Market By Technology-
• NGS
• Microarray
• PCR
• FISH
• Others
Genetic Screening Testing for Preventive Health Market By Application-
• Oncology
• Cardiovascular Diseases
• Reproductive Health
• Neurodegenerative Health
• Rare Diseases
• Others
Genetic Screening Testing for Preventive Health Market By End-User-
• Hospitals and Diagnostic Laboratories
• DTC Companies
• Genetic Counselling Services
• Other End-users
Genetic Screening Testing for Preventive Health Market By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.